Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression
The findings indicate that rMETase can overcome ultra-high doxorubicin resistance in fibrosarcoma cells, likely through targeting methionine addiction, a universal metabolic vulnerability of cancer. These results support the potential clinical application of methionine restriction therapy to treat doxorubicin-resistant STS.
Authors
- Michael Bouvet (ORCID: https://orcid.org/0000-0002-0086-2159)
- Hiroyuki Tsuchiya
- Byung Mo Kang (ORCID: https://orcid.org/0000-0003-0900-094X)
- Katsuhiro Hayashi (ORCID: https://orcid.org/0000-0001-8665-2154)
- Norio Yamamoto (ORCID: https://orcid.org/0000-0002-7250-625X)
- Shinji Miwa
- KOHEI MIZUTA
- Satoru Demura
- Takashi Higuchi (ORCID: https://orcid.org/0000-0003-3281-4669)
- Kentaro Igarashi (ORCID: https://orcid.org/0000-0003-2278-1736)
- Sei Morinaga (ORCID: https://orcid.org/0000-0003-2961-9432)
- Hiroaki Kimura (ORCID: https://orcid.org/0000-0003-2145-8726)
- Qinghong Han
- Robert M. Hoffman
Institutions
- Kanazawa University (JP)
- University of San Diego (US)
- University of California San Diego (US)
- AntiCancer (United States) (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.3389/fonc.2025.1704021
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00